Background: Parkinson disease (PD) is a developing neurodegenerative disorder with motor and non-motor symptoms for which conventional dopaminergic treatment has a limited long-term efficacy. In the past few years, novel stem cell treatment modality, adaptive deep brain stimulation (aDBS) and personalized medicine are offering additional options for effective and long-term treatment. 
Objective: The current work represents a revised synthesis of emergent therapy approaches in PD including interventional strategies based on the use of stem cells, adaptive DBS technology and personalized medicine approaches to improve clinical outcomes in PD patients.
Methodology: Clinically and analytically relevant data from 2015 to 2025 was systematically reviewed using PubMed, Scopus and Web of Science peer reviewed articles and clinical trials or experimental studies related to the included clinical study questions. To illustrate this new field of research, we reviewed studies on the efficacy, safety, patient selection and translational potential of treatments based on scientific research. 
Results: Stem cell transplantation seems to be a good candidate for replacement of dopamine neurons and a number of phase I & II clinical studies are showing improvement of motor score. Interestingly, we found that the adaptive DBS based on continuous evolution of neurophysiological biomarkers was superior to conventional DBS in terms of both suppression of motor fluctuations and suppression of side effects. Digitalization, genomics, imaging, and precision medicine: Digitalization of healthcare has resulted in new approaches to treating the patients, highly personalized, to improve the response rate and disease control. 
Conclusion: Stem cell therapy, adaptive DBS and personal medicine, when used together, are complementary and synergistic tools in the treatment of PD. Together they could transform clinical practice in the future by delivering patient specific, durable, enhanced therapeutic outcomes. More information from larger and more rigorous studies and reviews of long-term safety however is still pending.